The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...